{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:58:51Z","timestamp":1791082731179,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hepatectomy for hepatocellular carcinoma (HCC) beyond the Milan criteria is shown to be beneficial. However, a high rate of post-operative HCC recurrence hinders the long-term survival of the patients. This study aimed to investigate and compare the impacts of tenofovir (TDF) and entecavir (ETV) on the recurrence of hepatitis B viral (HBV)-related HCC beyond the Milan criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data pertaining to 1532 patients who underwent hepatectomy and received antiviral therapy between January 2014 and January 2019 were collected from five centers. Recurrence-free survival (RFS) analysis was performed using the Kaplan\u2013Meier method. Cox proportional hazards regression analysis was performed to determine prognostic factors for HCC recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The analysis incorporates 595 HBV-related HCC patients. The overall 5-year RFS was 21.3%. Among them, 533 and 62 patients received ETV and TDF treatment, respectively. The 1-, 3-, and 5-year RFS rates were 46.3%, 27.4%, and 19.6%, respectively, in the ETV group compared with 65.1%, 41.8%, and 37.2%, respectively, in the TDF group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001). Multivariate analysis showed that TDF treatment (hazard ratio [HR]: 0.604, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.005), cirrhosis (HR: 1.557, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.004), tumor size (HR: 1.037, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.008), microvascular invasion (MVI) (HR: 1.403, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.002), portal vein tumor thrombus (PVTT) (HR: 1.358, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.012), capsular invasion (HR: 1.228, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.040), and creatinine levels (CREA) (HR: 0.993, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.031) were statistically significant prognostic factors associated with RFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Patients with HCC beyond the Milan criteria exhibited a high rate of HCC recurrence after hepatectomy. Compared to the ETV therapy, TDF administration significantly lowered the risk of HCC recurrence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001864","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:20:27Z","timestamp":1640190027000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy"],"prefix":"10.1097","volume":"135","author":[{"given":"Junyi","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusheng","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan, Leshan, Sichuan 614700, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chinese Academy of Sciences, Chengdu, Sichuan 610072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"R5-20250603","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1245\/s10434-015-4929-x","article-title":"Surgical resection is better than transarterial chemoembolization for patients with hepatocellular carcinoma beyond the Milan criteria: a prognostic nomogram study","volume":"23","author":"Hsu","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jhep.2017.03.007","article-title":"The treatment of intermediate stage tumour beyond TACE: from surgery to systemic therapy","volume":"67","author":"Galle","year":"2017","journal-title":"J Hepatol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.29883","article-title":"Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies","volume":"68","author":"Hyun","year":"2018","journal-title":"Hepatology"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/SLA.0000000000003192","article-title":"Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide survey","volume":"272","author":"Fukami","year":"2020","journal-title":"Ann Surg"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000505093","article-title":"Comparison of partial hepatectomy and transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Labgaa","year":"2020","journal-title":"Liver Cancer"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/bjs.10541","article-title":"Survival benefit of liver resection for Barcelona clinic liver cancer stage B hepatocellular carcinoma","volume":"104","author":"Kim","year":"2017","journal-title":"Br J Surg"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jhep.2014.10.037","article-title":"Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona clinic liver cancer stages: a multicentre study","volume":"62","author":"Vitale","year":"2015","journal-title":"J Hepatol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/SLA.0000000000001866","article-title":"Liver resection and transplantation for patients with hepatocellular carcinoma beyond Milan criteria","volume":"264","author":"Zaydfudim","year":"2016","journal-title":"Ann Surg"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1245\/s10434-014-3621-x","article-title":"HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma","volume":"21","author":"Sohn","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/jvh.12911","article-title":"The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: a propensity score matching analysis","volume":"25","author":"Shen","year":"2018","journal-title":"J Viral Hepat"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jamcollsurg.2016.11.009","article-title":"Antiviral therapy inhibits viral reactivation and improves survival after repeat hepatectomy for hepatitis B virus-related recurrent hepatocellular carcinoma","volume":"224","author":"Huang","year":"2017","journal-title":"J Am Coll Surg"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","article-title":"Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial","volume":"268","author":"Huang","year":"2018","journal-title":"Ann Surg"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1136\/gutjnl-2019-320326","article-title":"Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis","volume":"69","author":"Teng","year":"2019","journal-title":"Gut"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2019","journal-title":"Gastroenterology"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis","volume":"69","author":"Lee","year":"2019","journal-title":"Gut"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.31289","article-title":"Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2021.02.019","article-title":"The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma","volume":"89","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1148\/radiol.15142394","article-title":"Single hepatocellular carcinoma: preoperative MR Imaging to predict early recurrence after curative resection","volume":"276","author":"An","year":"2015","journal-title":"Radiology"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT","volume":"61","author":"Yin","year":"2014","journal-title":"J Hepatol"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.28266","article-title":"Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation","volume":"63","author":"Lee","year":"2015","journal-title":"Hepatology"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-(3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN-lambda in murine tumor models","volume":"176","author":"Sato","year":"2006","journal-title":"J Immunol"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"e00140","DOI":"10.14309\/ctg.0000000000000140","article-title":"Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBVDNA but normal alanine aminotransferase","volume":"11","author":"Lee","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1245\/s10434-021-09673-w","article-title":"Microvascular invasion status and its survival impact in hepatocellular carcinoma depend on tissue sampling protocol","volume":"28","author":"Chen","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:07:03Z","timestamp":1748977623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001864","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}